Manfred Rüdiger
Director/Board Member at 4SC AG
Profile
Manfred Rüdiger is currently the Chief Executive Officer at Ariceum Therapeutics GmbH and the Chief Executive Officer & Managing Director at Satosea Oncology GmbH.
He is also the Vice Chairman-Supervisory Board at 4SC AG, the Chairman-Supervisory Board at Minaris Regenerative Medicine GmbH, the Chairman at Thermosome GmbH, and the Director at G2M Cancer Drugs AG.
In his former positions, Dr. Rüdiger served as the Chief Executive Officer at igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH, Affectis Pharmaceuticals AG, Kiadis Pharma BV, t2cure GmbH, Kiadis Pharma NV, and Igeneon AG.
He was also the Chief Executive Officer at CatalYm GmbH and the Managing Director at Kiadis Pharma Canada, Inc. and Kiadis Pharma Deutschland GmbH.
Additionally, he held the position of Chief Operating Officer at Aphton Corp.
and was the Chief Executive & Scientific Officer at Cardion GmbH.
He worked as an Assistant Professor at Technische Universität Braunschweig and was a Partner at LSP Services Deutschland GmbH.
Dr. Rüdiger also served as a Member-Supervisory Board at HeartBeat.bio AG.
Dr. Rüdiger completed his undergraduate studies at Eberhard Karls Universität Tübingen and obtained his doctorate from the Max Planck Institute For Biophysical Chemistry in 1994.
Manfred Rüdiger active positions
Companies | Position | Start |
---|---|---|
4SC AG | Director/Board Member | 2005-08-15 |
Satosea Oncology GmbH | Chief Executive Officer | - |
Thermosome GmbH
Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | Chairman | - |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Chairman | - |
G2M Cancer Drugs AG
G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Director/Board Member | 2009-11-23 |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Chief Executive Officer | 2020-12-31 |
Former positions of Manfred Rüdiger
Companies | Position | End |
---|---|---|
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Chief Executive Officer | 2021-02-27 |
Kiadis Pharma Deutschland GmbH
Kiadis Pharma Deutschland GmbH Pharmaceuticals: MajorHealth Technology Kiadis Pharma Deutschland GmbH develops drugs for blood cancer. The private company is based in Munich, Germany. | Chief Executive Officer | 2016-12-31 |
Kiadis Pharma Canada, Inc.
Kiadis Pharma Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kiadis Pharma Canada, Inc. manufactures and supplies pharmaceutical products. The company is based in Saint-Laurent, Canada. | Chief Executive Officer | 2016-12-31 |
░░░░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Manfred Rüdiger
Max Planck Institute For Biophysical Chemistry | Doctorate Degree |
Eberhard Karls Universität Tübingen | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
4SC AG | Health Technology |
Private companies | 18 |
---|---|
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Health Technology |
Kiadis Pharma Deutschland GmbH
Kiadis Pharma Deutschland GmbH Pharmaceuticals: MajorHealth Technology Kiadis Pharma Deutschland GmbH develops drugs for blood cancer. The private company is based in Munich, Germany. | Health Technology |
G2M Cancer Drugs AG
G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Commercial Services |
t2cure GmbH
t2cure GmbH Medical/Nursing ServicesHealth Services t2cure GmbH develops progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiovascular diseases like myocardial infarction or peripheral vascular diseases. The company was founded by Andreas M. Zeiher and Stefanie Dimmeler n 2005 and is headquartered in Frankfurt, Germany. | Health Services |
LSP Services Deutschland GmbH | Finance |
Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Health Technology |
Kiadis Pharma BV
Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Kiadis Pharma NV
Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Kiadis Pharma Canada, Inc.
Kiadis Pharma Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kiadis Pharma Canada, Inc. manufactures and supplies pharmaceutical products. The company is based in Saint-Laurent, Canada. | Health Technology |
Aphton Corp.
Aphton Corp. BiotechnologyHealth Technology Aphton Corp. operates as a biopharmaceutical company, which is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and gastrointestinal disease. The company was founded on May 12, 1981 and is headquartered in Philadelphia, PA. | Health Technology |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
Igeneon AG | |
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Health Technology |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Health Technology |
Heartbeat.bio AG
Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | Commercial Services |
Thermosome GmbH
Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | Health Technology |
Satosea Oncology GmbH | |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |
- Stock Market
- Insiders
- Manfred Rüdiger